Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) ...

As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

With a market cap of $138.2 billion, Pfizer Inc. (PFE) is a leading global biopharmaceutical company headquartered in New ...

China, licensing agreement with 3SBio, granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

NEW YORK - Pfizer Inc. (NYSE:PFE), a pharmaceutical giant with $62.46 billion in revenue and a market capitalization of $130.76 billion, has secured an exclusive licensing agreement with Chinese ...

Northeastern Chinese company 3SBio to receive $1.25B, in addition to $100M equity investment, $150M for exclusive rights in ...

The agreement also provides Pfizer the option of commercialization rights in China. 3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated ...

As Cantor Fitzgerald analyst Carter Gould put it, Pfizer's deal with 3SBio thrusts the company into the PD-1/VEGF race, but at "considerable" cost and "meaningfully behind" the competition.